SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Mar 10, 2020
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: March 10, 2020 · CIK: 0001614744 · Accession: 0001213900-20-005823
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235729
Letter
RE: Kitov Pharma Ltd.
March 10, 2020
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
Registration Statement on Form F-1
Filed December 27, 2019, as amended March 10, 2020
Request for Acceleration
File No. 333-235729
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-mentioned Registration Statement on Form F-1 (the “Registration Statement”) to 5:15 p.m., Eastern Time on March 11, 2020, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharma Ltd.
Show Raw Text
CORRESP
1
filename1.htm
March 10, 2020
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
RE:
Kitov Pharma Ltd.
Registration Statement on Form F-1
Filed December 27, 2019, as amended March 10, 2020
Request for Acceleration
File No. 333-235729
Ladies and Gentlemen:
Pursuant to Rule 461
of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities
Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date
of the above-mentioned Registration Statement on Form F-1 (the “Registration Statement”) to 5:15 p.m., Eastern
Time on March 11, 2020, or as soon thereafter as practicable.
Should any member of
the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact
our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharma Ltd.
By:
/s/ Isaac Israel
Isaac Israel
Chief Executive Officer
cc:
Rick A. Werner, Esq., Haynes and Boone, LLP
Jayun Koo, Esq., Haynes
and Boone, LLP
So Yung Kang, Esq.,
Haynes and Boone, LLP